Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 20;12(8):5107-5127.
doi: 10.1364/BOE.428143. eCollection 2021 Aug 1.

Hyperspectral imaging and robust statistics in non-melanoma skin cancer analysis

Affiliations

Hyperspectral imaging and robust statistics in non-melanoma skin cancer analysis

Lloyd A Courtenay et al. Biomed Opt Express. .

Abstract

Non-Melanoma skin cancer is one of the most frequent types of cancer. Early detection is encouraged so as to ensure the best treatment, Hyperspectral imaging is a promising technique for non-invasive inspection of skin lesions, however, the optimal wavelengths for these purposes are yet to be conclusively determined. A visible-near infrared hyperspectral camera with an ad-hoc built platform was used for image acquisition in the present study. Robust statistical techniques were used to conclude an optimal range between 573.45 and 779.88 nm to distinguish between healthy and non-healthy skin. Wavelengths between 429.16 and 520.17 nm were additionally found to be optimal for the differentiation between cancer types.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest related to this article

Figures

Fig. 1.
Fig. 1.
The hyperspectral pushbroom platform (80 × 25 cm) and system built for data acquisition purposes in the present study. (a & b) Multifunctional structure, composed of the sensor, halogen light illumination, and calibration marker board and frame. (c) Electronic module controller. (d) Power supply connected to the controller.
Fig. 2.
Fig. 2.
The marker board used for the calibration and correction of the hyperspectral images. (a) Spectralon reflectance pattern. (b) Region (marked in red) used to obtain reflectance values for all 270 bands of the camera
Fig. 3.
Fig. 3.
Examples of sampled hyperspectral curves from different patients. (a) A graphical description of the image acquisition workflow. (b) An example of (upper) Basal Cell Carcinoma, found under the hairline of the frontal portion of a male patient’s head, and (lower) a Squamous Cell Carcinoma found on the back of a female patient’s hand. (c) Examples of the hyperspectral signatures obtained for (upper) the Basal Cell Carcinoma patient (a-upper) and the Squamous Cell Carcinoma patient (a-lower).ç. Faces and distinguishing features have been excluded from these figures to ensure patient confidentiality.
Fig. 4.
Fig. 4.
Graphs presenting the logarithm of Shapiro-Wilks p-values as well as test statistics (w) for each of the samples across each of the bands. The solid horizontal line in each of the left-hand panels mark the p = log(0.003) threshold, that is, all log(p) values that fall below this line have less than a 5% chance of being false positives, and can thus be considered strong deviations from the normal distribution.
Fig. 5.
Fig. 5.
Graphs presenting p(H0) calibrations for each of the Shapiro-Wilks p-values in Fig. 4. Central values were calculated using 1:2 prior probabilities while confidence intervals mark upper bound 3:10 prior probabilities in favour of H0 and lower bound 7:10 prior probabilities in favour of H0.
Fig. 6.
Fig. 6.
Calculated residuals for fitted linear models across the entire spectrum analysed.
Fig. 7.
Fig. 7.
Sample skewness and kurtosis calculations across the entire spectrum analysed.
Fig. 8.
Fig. 8.
Hyperspectral signatures for each of the samples. (a) Robust signature marking the central tendency as well as 5% and 95% quantile confidence intervals (lower lines and upper lines respectively). (b) √BWMV calculations representing robust sample variance.
Fig. 9.
Fig. 9.
Univariate hypotheses test results comparing each of the samples across each of the hyperspectral bands using the Levene test for homoscedasticity. (a) Probability of Null Hypotheses (P(H0)) values, calibrated for each p-value using priors of 1:2 to mark the central tendency, while confidence intervals mark upper bounds using 3:10 prior probabilities in favour of H0 and lower bounds using 7:10 prior probabilities in favour of H0. (b) Test statistic calculations for each of the corresponding hypothesis tests.
Fig. 10.
Fig. 10.
Comparisons of samples using calculations of distribution similarities via Jensen-Shannon distance metricss.
Fig. 11.
Fig. 11.
Optimally defined windows as established by multiple methods within the present study. Area delimited by dotted vertical lines marks the final window of interest between 573.45 and 779.88 nm.
Fig. 12.
Fig. 12.
Visualisation of different skin lesions via single bands (611.18 nm and 735.49 nm) of hyperspectral images, as well as their corresponding RGB images. Channel bandwidths have been measured at 2.2 nm.

References

    1. Rogers H. W., Weinstock M. A., Harris A. R., Hinckley M. R., Feldman S. R., Fleischer A. B., Coldiron B. M., “Incidence estimage of nonmelanoma skin cancer in the United States, 2006,” Arch. Dermatol. 146(3), 283–287 (2010). 10.1001/archdermatol.2010.19 - DOI - PubMed
    1. Lomas A., Leonardi-Bee J., Bath-Hextall F., “A systematic review of worldwide incidence of nonmelanoma skin cancer,” Br. J. Dermatol. 166(5), 1069–1080 (2012). 10.1111/j.1365-2133.2012.10830.x - DOI - PubMed
    1. Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Wolkmer B., Greinert R., Breitbart E. W., Katalinic A., “Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence,” J. Invest. Dermatol. 134(1), 43–50 (2014). 10.1038/jid.2013.304 - DOI - PubMed
    1. Brunssen A., Waldmann A., Eisemann N., Katalinic A., “Impact of skin cancer screening and secondary prevention campagins on skin cancer incidence and mortality: a systematic review,” J. Am. Acad. Dermatol. 76(1), 129–139.e10 (2017). 10.1016/j.jaad.2016.07.045 - DOI - PubMed
    1. Diepgen T. L., Mahler V., “The epidemiology of skin cancer,” Br. J. Dermatol. Supplement 146(61), 1–6 (2002). - PubMed